年龄相关性黄斑变性患者的丙二醛水平:系统综述与荟萃分析
合并标准化均数差显示AMD患者MDA显著升高(1.91 µmol/L,95%CI 1.08-2.74,P<0.001),但研究间异质性极高(I=96.8%),结论需谨慎解读。
要点
- AMD患者血液MDA水平显著高于无AMD对照,合并SMD为1.91 µmol/L。
- 研究间异质性极高(I=96.8%),可能受发表偏倚影响。
- 年龄、样本基质和检测方法均一的5项研究合并后SMD为1.07 µmol/L,仍显著。
核心结论
- 有证据提示AMD患者MDA水平高于健康对照,但因异质性极高和可能的发表偏倚需谨慎解读。
- 在年龄、样本基质和MDA实验室检测均一的5项研究中,AMD患者MDA仍显著升高但效应减弱。
- 需未来年龄匹配良好的队列研究才能对MDA升高在AMD中的可能作用做出明确结论。
研究设计与样本
- 系统综述与荟萃分析,遵循MOOSE指南检索PubMed、ISI Web of Sciences和Scopus。
- 共评估634例AMD患者(平均年龄66.7岁)和656例无AMD对照(平均年龄67.8岁)。
- 采用随机效应模型合并数据,主要结局为湿性AMD和干性AMD,主要暴露变量为MDA水平。
主要发现
- 研究间异质性极高(I=96.8%,P<0.001)。
- 合并标准化均数差显示AMD患者MDA值显著更高(SMD=1.91 µmol/L,95%CI 1.08-2.74,P<0.001)。
- 在纳入5项年龄、样本基质和MDA实验室检测均一研究的模型中,异质性从极高降至中等(I=46.4%,P=0.113)。
- 该5项研究合并SMD虽减弱但仍显著更高(SMD=1.07 µmol/L,95%CI 0.82-1.31,P<0.001)。
关键数值与推荐
- 纳入标准为病例对照研究,参与者为AMD患者,对照为无AMD受试者。
- 主要结局指标为湿性AMD和干性AMD,主要暴露变量为MDA水平。
- 数据合并采用随机效应模型。
临床怎么用
- 当前证据不足以将血液MDA作为AMD的临床诊断或风险分层指标。
- 解读AMD患者MDA升高时应考虑研究间异质性和发表偏倚的可能影响。
- 未来需年龄匹配良好的队列研究进一步验证MDA在AMD中的潜在作用。
局限性
- 研究间异质性极高(I=96.8%)。
- 可能存在发表偏倚。
- 纳入研究均为病例对照设计,无法推断因果关系。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/PURPOSE: The role of blood malondialdehyde (MDA) in age-related macular degeneration (AMD), the leading cause of new blindness in industrialized countries, is still matter of debate. We performed a systematic review and meta-analysis of the published data on the MDA levels in AMD patients. METHODS: PubMed, ISI Web of Sciences, and Scopus searches were performed according to MOOSE guidelines. Case-control studies were eligible for inclusion. Participants and controls were AMD patients and subjects without AMD, respectively. The main outcome measures were wet AMD and dry AMD. MDA level was the main exposure variable. Data were pooled using a random-effects model. RESULTS: Twelve case-control studies were identified. A total of 634 AMD patients (mean age 66.7 years) and 656 controls without AMD (mean age 67.8 years) were evaluated. Extreme between-study heterogeneity was observed (I = 96.8%, P < 0.001). Pooled standardized mean difference showed that MDA values were significantly higher in patients with AMD (standardized mean difference = 1.91 µmol/L, 95% confidence interval = 1.08-2.74; P < 0.001). In a model including five studies, homogenous for age, sample matrix, and laboratory testing for MDA, heterogeneity decreased from extreme to moderate (I = 46.4%, P = 0.113), and pooled standardized mean difference, though attenuated, remained significantly higher in AMD patients (standardized mean difference = 1.07 µmol/L, 95% confidence interval = 0.82-1.31; P < 0.001). CONCLUSION: There is some evidence of higher levels of MDA in AMD patients compared with healthy controls; however, this result should be interpreted with caution because of extreme between-study heterogeneity and the possible effect of publication bias. Future studies, preferably well age-matched and of cohort design, are necessary before any firm conclusions on the putative role of elevated MDA on AMD can be drawn.
引用
- Pinna A, Boscia F, Paliogiannis P, et al. MALONDIALDEHYDE LEVELS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION: A Systematic Review and Meta-analysis. Retina. 2020. PMID: 31972788. doi:10.1097/IAE.0000000000002574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。